BioSpace News Archive

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 10,500 ordinary shares of Nabriva Therapeutics as an inducement to three newly-hired employees.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that it will report financial results and highlights for the quarter ended June 30, 2021 on Tuesday, Aug

Sprint Bioscience AB announces that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals.

Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent developments in its business.